CCNI2 and pancreatic neoplasm: High expression of CCNI2 was observed in 10 out of 32 cases of low-grade pancreatic cancer (WHO I-II; 31.25%) and in 20 out of 29 cases of high-grade pancreatic cancer (WHO III; 68.97%) (P ═ 0.007) (Table 2).